<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130036</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00033365</org_study_id>
    <nct_id>NCT03130036</nct_id>
  </id_info>
  <brief_title>Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease</brief_title>
  <acronym>AcAc PET</acronym>
  <official_title>Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Diet Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center imaging study that will recruit 60 participants who are enrolled in
      the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy
      for Amyloid Transformation in AD (BEAT-AD) Study protocol. This cohort of patients will
      receive a maximum of 3 [11C]Acetoacetate (AcAc)/[18F]Fluorodeoxyglucose (FDG) PET scans over
      18 weeks as part of this supplemental trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to examine the brain biodistribution of
      [11C]AcAc/[18F]FDG, a proxy for acetoacetate (ketone body)/glucose metabolism in 3 study
      groups; 1) those without identifiable risk of Alzheimer's disease, 2) asymptomatic
      individuals with increased risk of Alzheimer's disease (such as pre diabetes),and 3) those
      with early Alzheimer's disease or MCI. Secondary objectives include determining the
      association between adipose tissue distribution/function and biomarkers of AD pathology.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 9, 2015</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>No masking is used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Brain biodistribution of [11C]AcAc</measure>
    <time_frame>Baseline</time_frame>
    <description>To assess brain metabolism of ketones (cerebral metabolic rate of acetoacetate/micromilliliters/100 g/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain biodistribution of [11C]AcAc</measure>
    <time_frame>Change between baseline and four months</time_frame>
    <description>To assess change in brain metabolism of ketones (cerebral metabolic rate of acetoacetate/micromilliliters/100 g/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain biodistribution of [18F]FDG -</measure>
    <time_frame>Baseline</time_frame>
    <description>To assess brain uptake of glucose (cerebral metabolic rate of glucose /micromilliliters/100 g/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain biodistribution of [18F]FDG -</measure>
    <time_frame>Change between baseline and 4 months</time_frame>
    <description>To assess change in brain uptake of glucose (cerebral metabolic rate of glucose /micromilliliters/100 g/min)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>No risk of disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no identifiable risk of Alzheimer's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asymptomatic subjects with increased risk of Alzheimer's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early Alzheimer's or Mild Cognitive Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan</intervention_name>
    <description>A PET scan to measure uptake of acetoacetate and glucose in the brain will be administered to all participants enrolled in the study</description>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_label>Early Alzheimer's or Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>No risk of disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild cognitive impairment or subjective memory complaints

          -  Stable medical condition and medications

          -  Ability to complete baseline assessments

        Exclusion Criteria:

          -  History of a clinically significant stroke

          -  Sensory impairment (visual, auditory)

          -  Diabetes requiring medication

          -  Current use of cholesterol/lipid lowering medications, anticonvulsants, drugs with
             potential interfering CNS effects (other than cholinesterase inhibitors or memantine),
             medications with significant anticholinergic activity, anti-parkinsonian medications
             or regular use of narcotic analgesics

          -  Untreated hypothyroidism or B12 deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Craft, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Memory</keyword>
  <keyword>Cognitive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

